William L. Redmond

William L. Redmond

Auto-generated profile, based on publicly available information

William L. Redmond

Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
LELeisha A. Emens
Leisha A. Emens
PAPaolo A. Ascierto
Paolo A. Ascierto
Phil DarcyPhil Darcy
Phil Darcy
SDSandra Demaria
Sandra Demaria
AEAlexander M.M. Eggermont
Alexander M.M. Eggermont
FMFrancesco Marincola
Francesco Marincola

1 May 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
JWJohn M Wrangle
John M Wrangle
VVVamsidhar Velcheti
Vamsidhar Velcheti
MPManish R Patel
Manish R Patel
EGElizabeth Garrett-Mayer
Elizabeth Garrett-Mayer
EHElizabeth G Hill
Elizabeth G Hill
MRMark P Rubinstein
Mark P Rubinstein

12 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Julie N. GraffJulie N. Graff
Julie N. Graff
JAJoshi J. Alumkal
Joshi J. Alumkal
CDCharles G. Drake
Charles G. Drake
GTGeorge V Thomas
George V Thomas
WRWilliam L. Redmond
William L. Redmond
TBTomasz M. Beer
Tomasz M. Beer
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

16 February 2015 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SLStefanie Linch
Stefanie Linch
MMMichael J. McNamara
Michael J. McNamara
WRWilliam L. Redmond
William L. Redmond
Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilize the patient’s own immune system to destroy cancerous cells. Within a tumor the presence of a family of negative regulatory molecules, collectively known as “checkpoint inhibitors”, can inhibit T cell function to suppress anti-tumor immunity. Checkpoint inhibitors, such as CTLA-4 and PD-1, attenuate T cell proliferation and cytokine production. Targeted blockade of CTLA-4 or PD-1 with antagonist monoclonal antibodies (mAb) releases the “brakes” on T cells to boost anti-tumor immunity. Generating optimal “killer” CD8 T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through ligation of tumor necrosis factor receptor family members, including OX40 (CD134) and 4-1BB (CD137). OX40 is of particular interest as treatment with an activating (agonist) anti-OX40 mAb augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors. When used as single agents, these drugs can induce potent clinical and immunologic responses in patients with metastatic disease. However, each of these agents only benefits a subset of patients, highlighting the critical need for more effective combinatorial therapeutic strategies. In this review, we will discuss our current understanding of the cellular and molecular mechanisms by which OX40 agonists synergize with checkpoint inhibitor blockade to augment T cell-mediated anti-tumor immunity and the potential opportunities for clinical translation of combinatorial immunotherapeutic strategies.

20 February 2018 in OncoImmunology
Verified
Journal Article
Open access
MFMohammad Farhad
Mohammad Farhad
ARAnnah Rolig
Annah Rolig
WRWilliam L. Redmond
William L. Redmond
The efficacy of cancer immunotherapy is limited, in part, by the multitude of immunosuppressive mechanisms present within the tumor microenvironment (TME). Galectin-3 (Gal-3) is a lectin that contributes to TME immunosuppression and regulates diverse functions including cellular homeostasis and cancer biology. Increased Gal-3 expression during cancer progression augments tumor growth, invasiveness, metastatic potential, and immune suppression, which highlights the potential use of Gal-3 as a therapeutic target capable of modulating anti-tumor immunity. Here, we discuss the mechanisms by which Gal-3 regulates lymphocytes, the role of Gal-3 in lung and prostate tumors, and the contribution of Gal-3 to TME immunosuppression.

1 March 2005 in Immunity
Verified
Journal Article
Closed access
WRWilliam L. Redmond
William L. Redmond
LSLinda A. Sherman
Linda A. Sherman